<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00686088</url>
  </required_header>
  <id_info>
    <org_study_id>PRX302-1-02</org_study_id>
    <nct_id>NCT00686088</nct_id>
  </id_info>
  <brief_title>An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy</brief_title>
  <official_title>An Open-Label, Multi-Center, Phase IIa Trial of PRX302 Treatment of Patients With Locally Recurrent Prostate Cancer After Primary Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sophiris Bio Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Protox Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the therapeutic activity of different&#xD;
      concentrations of PRX302 at increasing volumes and/or number of deposits per gram of&#xD;
      prostate. Therapeutic activity will be determined based on changes in PSA levels, PSA&#xD;
      velocity, PSA doubling time and tumor burden following treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PSA levels, PSA doubling time, PSA velocity and tumor burden assessment by biopsy compared to screening.</measure>
    <time_frame>Day 45 and Day 180</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of PRX302.</measure>
    <time_frame>12 months.</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Locally Recurrent Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRX302</intervention_name>
    <description>Determination of the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Completed a full course of radiation therapy for prostate cancer at least 2 years&#xD;
             before enrollment.&#xD;
&#xD;
          -  Biochemical failure at screening as determined by either the ASTRO or the Phoenix&#xD;
             definitions.&#xD;
&#xD;
          -  At least 5 available PSA readings after completion of radiation therapy and prior to&#xD;
             screening.&#xD;
&#xD;
          -  PSA level of not greater than 10 ng/mL.&#xD;
&#xD;
          -  PSA doubling time of at least 9 months at screening.&#xD;
&#xD;
          -  Biopsy-proven recurrent localized prostate cancer.&#xD;
&#xD;
          -  Tumor stage T1C to T2C.&#xD;
&#xD;
          -  Prostate volume estimated at 40 mL or less as determined by TRUS.&#xD;
&#xD;
          -  ECOG performance score 0 to 2.&#xD;
&#xD;
          -  Serum testosterone of at least 1 ng/dL.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior history of metastatic prostate cancer.&#xD;
&#xD;
          -  Salvage external beam therapy and/or salvage brachytherapy prior to enrollment.&#xD;
&#xD;
          -  Biological, immunological, chemotherapeutic treatment or cryotherapy after completing&#xD;
             radiation.&#xD;
&#xD;
          -  Androgen ablation therapy within 12 months prior to enrollment.&#xD;
&#xD;
          -  Recurrence of prostate cancer within 18 months of definitive primary radiotherapy.&#xD;
&#xD;
          -  Other medication for prostate cancer.&#xD;
&#xD;
          -  Presence of active malignancy other than prostate cancer.&#xD;
&#xD;
          -  Treatment with other investigational therapies within 12 months prior to enrolment.&#xD;
&#xD;
          -  Presence of a chronic indwelling Foley catheter for obstructive uropathy.&#xD;
&#xD;
          -  Previous transurethral resection of the prostate (TURP), transurethral resection of&#xD;
             the bladder neck, photo-selective vaporization of the prostate (PVP) or other&#xD;
             resection surgery in the urinary tract.&#xD;
&#xD;
          -  Previous treatment with PRX302.&#xD;
&#xD;
          -  Any evidence of metastatic disease on bone scan, CT or magnetic resonance imaging&#xD;
             (MRI) within 3 months prior to enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Urology San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>May 26, 2008</study_first_submitted>
  <study_first_submitted_qc>May 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2008</study_first_posted>
  <last_update_submitted>October 27, 2009</last_update_submitted>
  <last_update_submitted_qc>October 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2009</last_update_posted>
  <responsible_party>
    <name_title>Rosemina Merchant, M.E.Sc., VP, Development and Regulatory Affairs</name_title>
    <organization>Protox Therapeutics</organization>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>locally recurrent</keyword>
  <keyword>PRX302</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

